P21
Also known as: P021
P21 (also P021) is a small peptidergic compound — the tetrapeptide core Asp-Gly-Gly-Leu with an N-terminal acetyl and a C-terminal adamantylated glycine amide (Ac-DGGL(A)G-NH2) — derived from an active region (residues ~148–151) of human ciliary neurotrophic factor (CNTF). It was designed and characterized in the Khalid Iqbal laboratory at the New York State Institute for Basic Research in Developmental Disabilities (NYS IBR). It is an experimental, preclinical compound — NOT FDA-approved and NOT tested in humans in published trials. Distinct from the cyclin-dependent kinase inhibitor protein p21/CDKN1A/WAF1 (a completely different gene product; the two share only the name).
0 listings, ranked by trust score
Each row is a (vendor, peptide) pair. Click through for the listing detail, the vendor's full trust profile, and any COAs they've published.
No vendors carrying this peptide are indexed yet.
COAs for P21
3 third-party tests across 1 vendor. Each card links to the full report.